Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 900-905

  Horan, John T ^a   Haight, Ann ^a   Dioguardi, Jacqueline Lagerlof ^b   Brown, Clark ^a   Grizzle, Audrey ^a   Shelman, Chiani ^a   Kanter, Julie ^c   Hale, Greg ^d   Nieder, Michael ^d   Benton, Melody ^e   Kasow, Kimberly A ^f   Abraham, Allistair ^b   Chiang, Kuang Yueh ^a  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^e TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Sickle cell disease; Transplant conditioning

Indexed keywords

AMLODIPINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETIRACETAM; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MAGNESIUM; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CEREBROVASCULAR DISEASE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTICENTER STUDY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESCHOOL CHILD; SCHOOL CHILD; SICKLE CELL ANEMIA; T LYMPHOCYTE; TREATMENT OUTCOME; ALLOGRAFT; ANALOGS AND DERIVATIVES; ANEMIA, SICKLE CELL; CLINICAL TRIAL; PROCEDURES;

ADOLESCENT; ALLOGRAFTS; ANEMIA, SICKLE CELL; ANTILYMPHOCYTE SERUM; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84928207399     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.015     Document Type: Article

References (29)

1. Bernaudin F., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007, 110:2749-2756.
2. Vermylen C., et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22:1-6.
3. Walters M.C., et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000, 95:1918-1924.
4. McPherson M.E., et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011, 46:27-33.
5. Diaconescu R., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004, 104:1550-1558.
6. Parker J.E., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002, 119:144-154.
7. Kelly M.J., et al. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer 2012, 59:725-731.
8. Brachet C., et al. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. JPediatr Hematol Oncol 2007, 29:445-450.
9. Walters M.C., et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010, 16:263-272.
10. Chakrabarti S., Bareford D. Asurvey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant 2007, 39:447-451.
11. Thompson A.L., et al. An educational symposium for patients with sickle cell disease and their families: results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. Pediatr Blood Cancer 2013, 60:1946-1951.
12. Solal-Celigny P., et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. JClin Oncol 1996, 14:514-519.
13. Andersson B.S., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
14. Bornhauser M., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102:820-826.
15. Childs R., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. NEngl J Med 2000, 343:750-758.
16. Khouri I.F., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
17. Ruiz-Arguelles G.J., et al. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol 2001, 66:241-244.
18. Slavin S., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
19. Baron F., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104:2254-2262.
20. Baron F., Sandmaier B.M. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006, 20:1690-1700.
21. Breuer S., et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 2012, 26:509-519.
22. Bearman S.I., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
23. Przepiorka D., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
24. Filipovich A.H., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Cho W.K., et al. Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern. JPediatr Endocrinol Metab 2011, 24:1031-1035.
26. Teinturier C., et al. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998, 22:989-994.
27. Walters M.C., et al. Bone marrow transplantation for sickle cell disease [see comments]. NEngl J Med 1996, 335:369-376.
28. McPherson M.E., et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010, 54:552-558.
29. Pereira J., Cretney C., Aster R.H. Variation of class I HLA antigen expression among platelet density cohorts: a possible index of platelet age?. Blood 1988, 71:516-519.